Cancer

News

Conservatives shy away from drug price debate in election ma...

The Conservative Party has pledged to encourage R&D in the UK’s life science industry should it win the December general election, with its manifesto shying away from the measures to cr

Partner Content

Partner Content

Understanding the evolving CAR-T market

In August 2017, Novartis made history after receiving FDA approval for Kymriah, the world’s first chimeric antigen receptor T-cell (CAR-T) therapy.

Views & Analysis

Four predictions on the future of personalised medicine

For as long as there have been people, there have been illness and disease to hobble them.

Views & Analysis

Demonstrating the value of RWE

A new cross-industry effort hopes to research the benefits of RWE and promote acceptance of alternatives to traditional trials.

Views & Analysis

QandA-Drapers-Jenna-Balestrini-on-the-future-of-CAR-T

Q&A: Draper’s Jenna Balestrini on the future of CAR-T

As exciting as CAR-T is, there are still myriad challenges preventing it from reaching its full potential.

News

Seattle Genetics plans to file breast cancer drug tucatinib

Seattle Genetics has announced plans to file its breast cancer drug tucatinib after the drug met targets in a heavily pre-treated group of patients with advanced disease.

Conservatives shy away from drug price debate in election ma...

Understanding the evolving CAR-T market

Four predictions on the future of personalised medicine

Demonstrating the value of RWE

Q&A: Draper’s Jenna Balestrini on the future of CAR-T

Seattle Genetics plans to file breast cancer drug tucatinib

Dexcom is first to join FDA/CMS health tech pilot

Discover a new era of healthcare panel engagement: Grounded ...

Cancer

Editor's Picks